DOVER Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that DOVER Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $1.78B | Feb 14, 2020 |
| FY2019 | Sep 30, 2019 | $1.83B | Feb 14, 2020 |
| FY2019 | Jun 30, 2019 | $1.81B | Feb 14, 2020 |
| FY2019 | Mar 31, 2019 | $1.72B | Feb 14, 2020 |
| FY2018 | Dec 31, 2018 | $1.81B | Feb 15, 2019 |
| FY2018 | Sep 30, 2018 | $1.75B | Feb 15, 2019 |
| FY2018 | Jun 30, 2018 | $1.80B | Feb 15, 2019 |
| FY2018 | Mar 31, 2018 | $1.64B | Feb 15, 2019 |
| FY2018 | Dec 31, 2017 | $1.75B | Feb 15, 2019 |
| FY2018 | Sep 30, 2017 | $1.75B | Feb 15, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.09B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $7.75B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $7.68B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $7.84B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $7.91B | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | $1.78B | Feb 12, 2021 |
| FY2020 | Sep 30, 2020 | $1.75B | Feb 12, 2021 |
| FY2020 | Jun 30, 2020 | $1.50B | Feb 12, 2021 |
| FY2020 | Mar 31, 2020 | $1.66B | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | $1.78B | Feb 12, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $2.02B | Feb 16, 2018 |
| FY2017 | Sep 30, 2017 | $2.01B | Feb 16, 2018 |
| FY2017 | Jun 30, 2017 | $1.99B | Feb 16, 2018 |
| FY2017 | Mar 31, 2017 | $1.81B | Feb 16, 2018 |
| FY2017 | Dec 31, 2016 | $1.78B | Feb 16, 2018 |
| FY2017 | Sep 30, 2016 | $1.71B | Feb 16, 2018 |
| FY2017 | Jun 30, 2016 | $1.69B | Feb 16, 2018 |
| FY2017 | Mar 31, 2016 | $1.62B | Feb 16, 2018 |
| FY2016 | Dec 31, 2015 | $1.69B | Feb 10, 2017 |
| FY2016 | Sep 30, 2015 | $1.79B | Feb 10, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.22B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.96B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $2.87B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $2.90B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $2.97B | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | $651.45M | Feb 12, 2021 |
| FY2020 | Sep 30, 2020 | $658.73M | Feb 12, 2021 |
| FY2020 | Jun 30, 2020 | $551.60M | Feb 12, 2021 |
| FY2020 | Mar 31, 2020 | $612.24M | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | $651.32M | Feb 12, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.09B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.70B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $1.06B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $1.07B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $1.12B | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | $182.11M | Feb 12, 2021 |
| FY2020 | Sep 30, 2020 | $200.30M | Feb 12, 2021 |
| FY2020 | Jun 30, 2020 | $124.77M | Feb 12, 2021 |
| FY2020 | Mar 31, 2020 | $176.28M | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | $168.12M | Feb 12, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.37B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.21B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $1.22B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $1.28B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $1.28B | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $932.99M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $974.89M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $843.11M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $806.89M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $708.97M | Feb 15, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $165.34M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $149.60M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $139.06M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $151.35M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $157.83M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $142.10M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $140.96M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $143.03M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $130.54M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $115.84M | Feb 15, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.84B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.75B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $1.65B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $1.63B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $1.69B | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $1.54B | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $1.60B | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $1.72B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $1.72B | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $1.52B | Feb 15, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.34B | Feb 9, 2024 |
| FY2023 | Dec 31, 2022 | $805.72M | Feb 9, 2024 |
| FY2023 | Dec 31, 2021 | $1.12B | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $1.10B | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $945.31M | Feb 11, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $220.26M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $167.53M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $183.41M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $211.08M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $171.47M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $165.69M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $186.80M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $170.99M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $170.07M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $139.58M | Feb 15, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.42B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $12.51B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $11.35B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $10.90B | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $10.40B | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $9.15B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $8.67B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $8.37B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $10.66B | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $10.12B | Feb 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.41B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $6.95B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $5.11B | Feb 13, 2026 |
| FY2025 | Dec 31, 2022 | $4.29B | Feb 13, 2026 |
| FY2024 | Dec 31, 2021 | $4.19B | Feb 14, 2025 |
| FY2023 | Dec 31, 2020 | $3.39B | Feb 9, 2024 |
| FY2022 | Dec 31, 2019 | $3.03B | Feb 10, 2023 |
| FY2011 | Dec 31, 2011 | $4.93B | Feb 10, 2012 |
| FY2011 | Dec 31, 2010 | $4.53B | Feb 10, 2012 |
| FY2010 | Dec 31, 2009 | $4.08B | Feb 11, 2011 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.43B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $4.91B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $4.64B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $4.43B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $4.56B | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $4.07B | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $3.78B | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $3.68B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $3.69B | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $3.67B | Feb 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.22B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $13.41B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $11.00B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $10.22B | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $9.45B | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $8.61B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $8.21B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $7.82B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $8.46B | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $7.93B | Feb 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $513.08M | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | $397.25M | Feb 12, 2021 |
| FY2020 | Dec 31, 2018 | $396.22M | Feb 12, 2021 |
| FY2020 | Dec 31, 2017 | $753.96M | Feb 12, 2021 |
| FY2019 | Dec 31, 2016 | $349.15M | Feb 14, 2020 |
| FY2018 | Dec 31, 2015 | $362.19M | Feb 15, 2019 |
| FY2017 | Dec 31, 2014 | $681.58M | Feb 16, 2018 |
| FY2016 | Dec 31, 2013 | $803.88M | Feb 10, 2017 |
| FY2015 | Dec 31, 2012 | $800.08M | Feb 12, 2016 |
| FY2014 | Dec 31, 2011 | $1.21B | Feb 13, 2015 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.33B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.93B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $2.99B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $2.94B | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $3.02B | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $3.11B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $2.99B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $2.94B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $3.34B | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $3.21B | Feb 16, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 19 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 7 | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 7 | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Feb 12, 2021 |
| FY2020 | Sep 30, 2020 | 1 | Feb 12, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 12, 2021 |
| FY2020 | Mar 31, 2020 | 1 | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Feb 12, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 19 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 7 | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 7 | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Feb 12, 2021 |
| FY2020 | Sep 30, 2020 | 1 | Feb 12, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 12, 2021 |
| FY2020 | Mar 31, 2020 | 1 | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Feb 12, 2021 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $283.01M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $283.12M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $284.30M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $287.55M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $286.90M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $284.31M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $282.20M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $283.57M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $283.96M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $267.74M | Feb 15, 2019 |